T cell response to Dengue virus serotype 3 in mice and humans
小鼠和人类中 T 细胞对登革热病毒血清型 3 的反应
基本信息
- 批准号:8234188
- 负责人:
- 金额:$ 26.34万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-03-01 至 2014-02-28
- 项目状态:已结题
- 来源:
- 关键词:Animal ModelAntibodiesAntibody FormationAntiviral AgentsAsiaBiological AssayCD8B1 geneCell LineCellsCollaborationsConsensus SequenceCountryCulicidaeCytokine ActivationDataDengueDengue Hemorrhagic FeverDengue Shock SyndromeDengue VirusDiseaseEpidemicEpidemiologic StudiesEpitopesEquilibriumGenotypeHumanHuman VolunteersImmune responseImmunityImmunizationIndividualInfectionInterferonsLatin AmericaMediatingModelingMusNaturePathogenesisPathologyPeptidesPeripheral Blood Mononuclear CellProductionResearchRoleSamplingSerotypingSpecificitySplenocyteT cell responseT memory cellT-LymphocyteTestingTransgenic MiceVaccinesVariantViralViral ProteinsVirusVirus Diseasesbasebiodefensecytotoxicenzyme linked immunospot assaygain of functionimmunopathologyin vivoloss of functionmouse modelreceptorresponsetherapy developmentvaccine candidate
项目摘要
The four serotypes of Dengue virus (DENV) cause dengue fever (DF) and dengue hemorrhagic
fever/dengue shock syndrome (DHF/DSS) in humans. Studies suggest that DHF/DSS is an
immunopathogenic disease in which T cell responses may be dysregulated. Understanding the
mechanisms that regulate the balance between T cell mediated pathology versus protection is crucial for
developing therapies and, importantly, a safe dengue vaccine. By alternately passaging a DENV
between mice and mosquito cells, we have naturally selected for strains that induce robust T cell
responses in mice, and we have demonstrated a critical role for CD8+ T cells in limiting DENV infection
in mice. Due to the broad specificity and antiviral role of the CD8+ T cell response to DENV2 in mice, we
hypothesize that the murine and human CD8+ T cell response to DENV3 is broad, targeting most viral
proteins, and these CD8+ T cells protect against DENV3 infection in the host. Specifically, we will
examine the contribution of CD8+ T cells to protection versus pathogenesis using a mouse model of
DENV3 infection (Aims 1 and 2), and we will define the specificity and role of human CD8+ T cell
response in the host response to DENV3 infection using HLA transgenic mice and samples derived from
people who have recovered from primary DENV3 infection (Aims 3 and 4). This project focuses on
DENV3 because epidemiologic studies suggest that certain DENV serotypes, genotypes, and the
sequence of DENV infections may be associated with DHF/DSS, and little is known about DENV3
infection as compared with DENV2, although DENV3 co-circulates with DENV2 in endemic countries,
and DENV3 has been responsible for recent epidemics in South Asia and Latin America.
登革病毒(DENV)的四种血清型引起登革热(DF)和出血性登革
登革热/登革热休克综合征(DHF/DSS)。研究表明DHF/DSS是一种
T细胞应答可能失调的免疫病原性疾病。了解
调节T细胞介导的病理与保护之间的平衡的机制对于
开发治疗方法,更重要的是,开发安全的登革热疫苗。通过交替传代DENV
在小鼠和蚊子细胞之间,我们自然地选择了诱导强大T细胞的菌株,
我们已经证明了CD 8 + T细胞在限制DENV感染中的关键作用,
对小鼠由于小鼠中CD 8 + T细胞对DENV 2应答的广泛特异性和抗病毒作用,我们
假设鼠和人CD 8 + T细胞对DENV 3的应答是广泛的,靶向大多数病毒,
这些CD 8 + T细胞保护宿主免受DENV 3感染。具体来说,我们将
使用小鼠模型检查CD 8 + T细胞对保护作用与发病机制的贡献。
DENV 3感染(目的1和2),我们将确定人CD 8 + T细胞的特异性和作用,
使用HLA转基因小鼠和来源于DENV 3感染的样品,
从原发性DENV 3感染中康复的人(目标3和4)。该项目的重点是
DENV 3,因为流行病学研究表明,某些DENV血清型,基因型,
登革病毒感染顺序可能与DHF/DSS有关,而登革病毒3型(DENV 3)的感染顺序尚不清楚
感染与DENV 2相比,尽管DENV 3与DENV 2在流行国家共传播,
DENV 3是南亚和拉丁美洲最近流行的原因。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sujan Shresta其他文献
Sujan Shresta的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sujan Shresta', 18)}}的其他基金
Maternal Antibody-Mediated Enhancement of Dengue Pathogenesis
母体抗体介导的登革热发病机制增强
- 批准号:
10366012 - 财政年份:2021
- 资助金额:
$ 26.34万 - 项目类别:
Development of a Replicon RNA-based Vaccine against Dengue and Zika
开发基于复制子 RNA 的登革热和寨卡疫苗
- 批准号:
10413253 - 财政年份:2021
- 资助金额:
$ 26.34万 - 项目类别:
Maternal Antibody-Mediated Enhancement of Dengue Pathogenesis
母体抗体介导的登革热发病机制增强
- 批准号:
10212141 - 财政年份:2021
- 资助金额:
$ 26.34万 - 项目类别:
Maternal Antibody-Mediated Enhancement of Dengue Pathogenesis
母体抗体介导的登革热发病机制增强
- 批准号:
10581624 - 财政年份:2021
- 资助金额:
$ 26.34万 - 项目类别:
Development of a Replicon RNA-based Vaccine against Dengue and Zika
开发基于复制子 RNA 的登革热和寨卡疫苗
- 批准号:
10281127 - 财政年份:2021
- 资助金额:
$ 26.34万 - 项目类别:
Development of a Replicon RNA-based Vaccine against Dengue and Zika
开发基于复制子 RNA 的登革热和寨卡疫苗
- 批准号:
10626835 - 财政年份:2021
- 资助金额:
$ 26.34万 - 项目类别:
Targeting Angiogenesis Pathways for Therapeutic Protection against Dengue
针对登革热治疗性保护的血管生成途径
- 批准号:
9223436 - 财政年份:2017
- 资助金额:
$ 26.34万 - 项目类别:
T cell response to Dengue virus serotype 3 in mice and humans
小鼠和人类中 T 细胞对登革热病毒血清型 3 的反应
- 批准号:
8375880 - 财政年份:2012
- 资助金额:
$ 26.34万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 26.34万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 26.34万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 26.34万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 26.34万 - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 26.34万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 26.34万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 26.34万 - 项目类别:
Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 26.34万 - 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 26.34万 - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
$ 26.34万 - 项目类别: